Biological
MVA-BN smallpox vaccine clinical trials
Also written IMVAMUNE and MVA-BN.
How studies write it
Studies that test it under each name
Other names
Studies by the year they started
31 studies that test it; most in 2005 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Smallpox
- 15
Who runs them
Industry 17 · Other 14
Bavarian Nordic (15) · National Institute of Allergy and Infectious Diseases (NIAID) (10) · McMaster University (1) · Centers for Disease Control and Prevention (1) · Janssen Research & Development, LLC (1) · Sanofi Pasteur, a Sanofi Company (1) · Muhimbili University of Health and Allied Sciences (1) · Ivan Litvinov (1)
Often tested with
Tested in the same studies.
Shingrix (1) · Escherichia coli lipopolysaccharide (1) · Candida albicans Antigen Injection (1)
Studies
Open first, then newest update. How each study uses MVA-BN smallpox vaccine is read from its arms, and is right about nine times in ten.
Testing it · 31
- Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCTActive, not recruitingPhase 4McMaster UniversityNCT05745987Written as Bavarian Nordic smallpox vaccine
- JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the CongoCompletedPhase 3Centers for Disease Control and PreventionNCT02977715Written as JYNNEOS (Liquid Formulation)
- Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox VaccineCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05512949Written as JYNNEOS
- Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsActive, not recruitingPhase 2Bavarian NordicNCT07199569Written as Jynneos
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for MpoxCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05740982Written as JYNNEOS
- Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRCCompletedPhase 4National Institute of Allergy and Infectious Diseases (NIAID)NCT05734508Written as MVA-BN vaccine
- Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus InfectionsActive, not recruitingPhase 2Bavarian NordicNCT06549530Written as MVA-BN
- MVA Post-Event: Administration Timing and Boost StudyCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00437021Written as MVA Smallpox Vaccine
- High Dose IMVAMUNE® in Vaccinia-Naive IndividualsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00879762Written as MVA Smallpox Vaccine
- A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy ParticipantsCompletedEarly Phase 1Janssen Research & Development, LLCNCT03953196Written as Imvanex
- Imvamune Vaccine for the Treatment of Non-melanoma Skin CancerTerminatedPhase 1/2Ivan LitvinovNCT04410874Written as Imvamune
- Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered IntradermallyCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00914732Written as MVA Smallpox Vaccine
- Special Access Program IMVAMUNE®CompletedPhase 4Bavarian NordicNCT03472014Written as IMVAMUNE®
- Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV InfectionCompletedPhase 2Bavarian NordicNCT02038881Written as IMVAMUNE®
- A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®CompletedPhase 3Bavarian NordicNCT01913353Written as MVA BN®
- An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 VaccineesCompletedPhase 2Bavarian NordicNCT00686582Written as IMVAMUNE
- A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy SubjectsCompletedPhase 2Bavarian NordicNCT00316524Written as MVA-BN® (IMVAMUNE)
- Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic DisordersCompletedPhase 1Bavarian NordicNCT00189917Written as IMVAMUNE (MVA-BN)
- Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.CompletedPhase 2Bavarian NordicNCT00189956Written as IMVAMUNE (MVA-BN)
- A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced SubjectsCompletedPhase 2Bavarian NordicNCT00857493Written as IMVAMUNE
See all 31 studies that test MVA-BN smallpox vaccine →
Given in every arm · 2 — MVA-BN smallpox vaccine is usual care beside what is tested
- Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug UseRecruitingPhase 4University of Alabama at BirminghamNCT06829238Written as Jynneos
- A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and MozambiqueCompletedPhase 2Muhimbili University of Health and Allied SciencesNCT01697007Written as Modified Vaccinia Ankara (MVA-CDMR)
As the comparator · 2 — what is tested is compared with MVA-BN smallpox vaccine
- Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the CongoNot yet recruitingPhase 2Shanghai Institute Of Biological ProductsNCT07253675Written as MVA-BN
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02743455Written as MVA Smallpox Vaccine
Codes
What other systems call MVA-BN smallpox vaccine · ClinicalTrials.gg INT005249
- MeSH (NLM) C527606smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordicConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) TU8J357395VACCINIA VIRUS MODIFIED STRAIN ANKARA-BAVARIAN NORDIC NON-REPLICATING ANTIGENConfirmed FDA, NLM, Wikidata
- Wikidata Q18358151MVA-BN smallpox vaccineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C173552MVA-BN Smallpox VaccineConfirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C527606 | smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | TU8J357395 | VACCINIA VIRUS MODIFIED STRAIN ANKARA-BAVARIAN NORDIC NON-REPLICATING ANTIGEN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q18358151 | MVA-BN smallpox vaccine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C173552 | MVA-BN Smallpox Vaccine | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.